SMAD6 Antibody
Purified Mouse Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | O43541 |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Clone Names | 5H3 |
Isotype | IgG1 |
Calculated MW | 53kDa |
Description | Antagonist of signaling by TGF-beta (transforming growth factor) type 1 receptor superfamily members; has been shown to inhibit selectively BMP (bone morphogenetic proteins) signaling by competing with the co-SMAD SMAD4 for receptor-activated SMAD1. SMAD6 is an inhibitory SMAD (I-SMAD) or antagonistic SMAD. Binds to regulatory elements in target promoter regions.Tissue specificity: Ubiquitous in various organs, with higher levels in lung. Isoform B is up-regulated in diseased heart tissue. |
Immunogen | Purified recombinant fragment of human SMAD6 expressed in E. Coli. |
Formulation | Ascitic fluid containing 0.03% sodium azide. |
Gene ID | 4091 |
---|---|
Other Names | Mothers against decapentaplegic homolog 6, MAD homolog 6, Mothers against DPP homolog 6, SMAD family member 6, SMAD 6, Smad6, hSMAD6, SMAD6, MADH6 |
Dilution | WB~~1/500 - 1/2000 |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | SMAD6 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | SMAD6 |
---|---|
Synonyms | MADH6 |
Function | Transforming growth factor-beta superfamily receptors signaling occurs through the Smad family of intracellular mediators. SMAD6 is an inhibitory Smad (i-Smad) that negatively regulates signaling downstream of type I transforming growth factor-beta (PubMed:10647776, PubMed:10708948, PubMed:10708949, PubMed:16951688, PubMed:22275001, PubMed:30848080, PubMed:9436979, PubMed:9759503). Acts as a mediator of TGF-beta and BMP anti-inflammatory activities. Suppresses IL1R-TLR signaling through its direct interaction with PEL1, preventing NF-kappa-B activation, nuclear transport and NF-kappa-B- mediated expression of pro-inflammatory genes (PubMed:16951688). Blocks the BMP-SMAD1 signaling pathway by competing with SMAD4 for receptor- activated SMAD1-binding (PubMed:30848080, PubMed:9436979). Binds to regulatory elements in target promoter regions (PubMed:16491121). |
Cellular Location | Nucleus. |
Tissue Location | [Isoform B]: Expressed in the brain, heart, ovary, peripheral blood leukocytes, small intestine, spleen, thymus, bone marrow, fetal liver and lymph nodes. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
1. J Biol Chem. 2006 Feb 10;281(6):3569-76. 2. Nat Immunol. 2006 Oct;7(10):1057-65. 3. J Med Genet. 2009 May;46(5):331-7.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.